Financial Data and Key Metrics Changes - The company aims to improve patient sustainability and reduce dropout rates, with a target to increase treatment adherence by even 10%, potentially preventing a quarter million people from going blind in the U.S. alone [16][5][6] Business Line Data and Key Metrics Changes - The company is focused on developing a retina-targeted drug, ex Paxley, with two main goals: enhancing sustainability of treatment and improving long-term outcomes for patients [4][7] Market Data and Key Metrics Changes - The dropout rate for anti-VEGF treatments in the U.S. is reported at 40%, which is significantly higher than in other markets, indicating a substantial opportunity for the company's product [15][16] Company Strategy and Development Direction - The company has redefined its identity to focus on retina treatments, emphasizing the need for sustainable therapies that address the long-term outcomes of patients suffering from retinal diseases [3][4][9] - The strategic approach includes a two-phase clinical trial design (SOUL one and SOLAR) that complements each other, aiming for regulatory approval and commercial advantage [34][40][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory pathway for their product, highlighting that they are following FDA guidelines closely, which positions them favorably compared to competitors [18][20] - The company is optimistic about the upcoming results from the SOLAR trial and its potential impact on the market, particularly in the diabetic retinopathy and diabetic macular edema segments [61][62] Other Important Information - The company has amended its trial design to enhance patient retention and meet FDA safety requirements, reducing the number of patients needed for the SOLAR study, which is expected to expedite the process [59][58] Q&A Session Summary Question: What is the company's strategy in the current competitive landscape? - The company aims to address the high dropout rates associated with existing treatments and believes that improving sustainability can significantly impact patient outcomes [16][5] Question: How does the company ensure the robustness of its clinical trials? - The company emphasizes careful patient selection and trial design to mitigate risks and enhance the likelihood of success, ensuring that the studies are conducted according to FDA guidelines [29][34] Question: What are the expectations for the upcoming SOLAR trial? - Management is confident that the trial will yield positive results, with a focus on patient retention and adherence to treatment protocols, which are critical for the trial's success [50][52]